My research is focused on the application of stem cells to examine the underlying molecular mechanisms that mediate neurodegenerative disease and to identify novel therapeutic approaches to treat these disorders. Many of my studies have focused on the most common age-related neurodegenerative disorder, Alzheimer's disease. However, building upon these studies we are examining the use of stem cells to study and treat related neurological disorders such as Parkinson's disease (PD), and Dementia with Lewy Bodies (DLB). We are also adapting molecular biological techniques for the study of embryonic and adult stem cells and to facilitate the purification, analysis, and transplantation of distinct neuronal and glial cell populations.
Joy Yu Zuchero is a Scientist/Pathway Leader at Denali Therapeutics. Previously, she spent 6 years in Genentech's Neuroscience department studying blood-brain barrier biology and antibody transport to the CNS. Her work has focused on utilizing the transferrin receptor as a platform for therapeutic antibody transport across the blood-brain barrier for Alzheimer's disease. Joy received her PhD in neuroscience from UCSF in 2009, where she studied neuronal trafficking of opioid receptors in response to drugs of abuse.
Dr. Olinger is the principal advisor science for MRI Global Inc. and is the high containment coordinator at the NIH NIAID Integrated Research Facility (IRF) in Frederick MD. In this role, he oversees the contract personnel and manages the coordination of research focused on high consequence pathogens utilizing state of the art medical imaging technology. Dr. Olinger is an international recognized expert in virology and immunology, especially for high consequence viral pathogens. During his twelve year tenure in the Virology Division of USAMRIID, he and his team conducted applied research with an emphasis on the development of medical countermeasures against viral biothreat agents, specifically highly lethal viral hemorrhagic fever viruses (VHFV). This included the co-development of a passive immune drug for Ebola, ZMapp and input on many of the vaccines developed to prevent infection. Since 2010, Dr. Olinger has maintained an adjunct associate Professor of Medicine in the Department of Infectious Disease appointment at the Boston University School of Medicine and a joint appointment to the National Emerging Infectious Diseases Laboratory (NEIDL) as the Associate Director for High Containment Training and an investigator with the Collaborative Core of the NEIDL. Dr. Olinger is active in multiple STEM programs and mentors high school, undergraduate graduate students and post-doctoral fellows.
Dr. Shiu-Lok Hu obtained his B. A. degree in Biochemistry from the University of California, Berkeley, Ph. D. degree in Molecular Biology from the University of Wisconsin, Madison, and post-doctoral training in tumor virology with Dr. Joe Sambrook in Cold Spring Harbor Laboratory. He began AIDS vaccine work in 1985 when he joined a biotech company in Seattle, which later became a part of the Bristol-Myers Squibb Pharmaceutical Research Institute. During his employment at Bristol-Myers Squibb (1985-1997), he developed the first recombinant virus vector as a candidate vaccine against HIV-1 and pioneered the “prime-boost” immunization strategy against primate immunodeficiency virus infection in a non-human primate model for AIDS. He joined the faculty at the University of Washington, Seattle, in 1997 to continue the pursuit of AIDS vaccine research. He currently holds the Milo Gibaldi Endowed Professorship of Pharmaceutics in the School of Pharmacy, University of Washington. He is also an Adjunct Professor in the Department of Microbiology in the School of Medicine and the Head of the AIDS-Related Research Division in the Washington National Primate Research Center. His research focuses on novel vaccine designs against HIV-1 and non-human primate models to study prophylactic and therapeutic approaches against HIV/AIDS.
Dr. Wiltzius is an associate director of target biology at Kite Pharma in Santa Monica. His responsibilities include discovery, validation, and prioritization of programs within Kite’s pipeline. His role at Kite also includes platform engineering and evolution of novel chimeric antigen receptors (CARs) and T cell receptors (TCRs). Prior to joining Kite, Dr. Wiltzius was a scientist in Oncology Research at Amgen. He was a project lead for several programs utilizing the Bispecific T cell Engager (BiTE) platform, following up with targets that he identified while part of a target discovery group at Amgen called the Genome Analysis Unit. Dr. Wiltzius received his B.S. in Biochemistry from the University of Wisconsin-Madison and his Ph.D. in Biochemistry from UCLA in the laboratory of Prof. David Eisenberg.
Dr. Partow Kebriaei is an Associate Professor in the Department of Stem Cell Transplant and Cellular Therapy at the MD Anderson Cancer Center in Houston, Texas. She completed her Hematology and Oncology fellowship training at the University of Chicago, and began her tenure at MD Anderson in 2003. Dr. Kebriaei’s research interests include therapy of leukemias, in particular acute lymphoblastic leukemia, as well as autologous and allogeneic stem cell transplantation for lymphoma and leukemia. She is interested in the development of novel transplant preparative regimens that may have less regimen-related toxicity, and increased disease efficacy. More specifically, she is interested in investigating the use of traditional chemotherapeutic agents in combination with cellular therapies and adoptive immunotherapy to develop more effective treatment regimens. Work toward this aim includes investigating the use of CD19-directed T cell therapy for lymphoid malignancies to augment the graft versus leukemia effect, and investigating the use of mesenchymal stem cells for the therapy of graft versus host disease. Dr. Kebriaei has authored numerous reviews, book chapters, and papers, and serves as a reviewer for major hematology and oncology publications. She is an active member of hematology and oncology professional societies including American Association for Cancer Research, American Society of Hematology, American Society of Clinical Oncology, and American Society for Blood and Marrow Transplantation.
Dr. Ponce is a Scientific Director in the Comparative Biology and Safety Assessment group at Amgen (Seattle, WA). Prior to this position he was Director of Preclinical Safety Assessment at ZymoGenetics, Inc. (Seattle, WA). He has previously worked as a research toxicologist at SNBL USA and the University of Washington, and as a toxicologist for the Alaska Department of Health and Social Services. Dr. Ponce is an Affiliate Associate Professor in the Department of Environmental and Occupational Health Sciences, University of Washington and is a Diplomate of the American Board of Toxicology.